Mylan Inc. has begun shipping doxycycline hyclate delayed-release tablets (150 mg), an oral antibiotic, after a favorable ruling in a patent infringement lawsuit brought by Warner Chilcott.


Mylan, doxycycline hyclate delayed-release tablets, Doryx, Doryx generic, oral antibiotic, Mylan Pharmaceuticals, Warner Chilcott, Mayne Pharma, patent infringement lawsuit, generic version of Doryx, tetracycline-class antimicrobial


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

First Doryx generic is released by Mylan

May 1st, 2012

PITTSBURGH – Mylan Inc. has begun shipping doxycycline hyclate delayed-release tablets (150 mg), an oral antibiotic, after a favorable ruling in a patent infringement lawsuit brought by Warner Chilcott.

The product is the first generic version of Doryx 150 mg, developed by Mayne Pharma and marketed by Warner Chilcott, according to Mylan.

A tetracycline-class antimicrobial, doxycycline hyclate DR tablets 150 mg had U.S. sales of $264.1 million in 2011, according to IMS Health figures reported by Mylan, whose Mylan Pharmaceuticals subsidiary launched the new product.

Warner Chilcott said Monday that the U.S. District Court for the District of New Jersey upheld the validity of the U.S. patent covering the company's Doryx 150 mg product but ruled that proposed generic versions from Mylan and Impax Pharmaceuticals didn't infringe on the branded product's patent. Warner Chilcott added that it's reviewing the court's decision and intends to appeal the noninfringement determinations.

Advertisement